First (18)F-labeled ligand for PET imaging of uPAR: In vivo studies in human prostate cancer xenografts
Research output: Contribution to journal › Journal article › peer-review
Urokinase-type plasminogen activator receptor (uPAR) is overexpressed in human prostate cancer and uPAR has been found to be associated with metastatic disease and poor prognosis. AE105 is a small linear peptide with high binding affinity to uPAR. We synthesized an N-terminal NOTA-conjugated version (NOTA-AE105) for development of the first (18)F-labeled uPAR positron-emission-tomography PET ligand using the Al(18)F radiolabeling method. In this study, the potential of (18)F-AlF-NOTA-AE105 to specifically target uPAR-positive prostate tumors was investigated.
Original language | English |
---|---|
Journal | Nuclear Medicine and Biology |
Volume | 40 |
Issue number | 5 |
Pages (from-to) | 618-24 |
Number of pages | 7 |
ISSN | 0969-8051 |
DOIs | |
Publication status | Published - Jul 2013 |
ID: 45945354